Skip to Main Content

Paper Details

SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Nat Microbiol
242
2021
ACE2, B.1.1.7 (Alpha), B.1.620, B1.351, COVID-19, E484K, Gamma, N501Y, P, Q498R, RBD, RBD-, RBD-62, S477N, SARS, SARS-, SARS-CoV, SARS-CoV-2, amino acid, angiotensin-converting enzyme 2
Author NameAffiliation
Orly DymWeizmann Institute of Science
Gideon SchreiberWeizmann Institute of Science
  • 1 - 2

Datasets

Release 1.2